The transition from Relapsing-Remitting MS (RRMS) to Secondary Progressive MS (SPMS) is traditionally viewed as a shift toward a steady, gradual accumulation of disability. But what if we could halt that progression entirely—without the lifelong dependency on neurosuppressive therapies?

I am incredibly proud to share a landmark clinical case from our R&D and biologics teams at Somata Genesis, Inc., demonstrating a remarkable therapeutic reversal in a highly complex SPMS case.

The Clinical Challenge

Our patient, Caroline Nunan, presented with an EDSS score of 6.5, navigating significant lifestyle challenges. Her SPMS was compounded by a highly complex comorbidity profile, including cardiomyopathy (a lasting effect of chemotherapy for Hodgkin’s Lymphoma in her youth), pulmonary arterial hypertension, osteoporosis, and structural cerebrovascular bottlenecks, specifically a narrowed left internal jugular vein leading to heightened intracranial pressure.

She was heavily dependent on a wheelchair and relied on a polypharmacy regimen across five medical specialties, including Ocrevus, Cymbalta, and Fampyra to manage spasticity and disease progression.

The Intervention: Caroline underwent our proprietary Neural Cell Transplant (NCT) protocol, coupled with a targeted cerebrovascular intervention to correct venous drainage and relieve intracranial pressure. To ensure the biological integration of the NCT protocol, she made the courageous decision to strictly discontinue her MS neurosuppressants, including her daily Fampyra.

1-Year Outcomes: NEDA Achieved At her 12-month follow-up, the clinical and radiological data speak volumes:

• Disease Halting: MRI confirms No Evidence of Disease Activity (NEDA). The progressive SPMS pathology has stabilized.
• Medication Independence: Caroline remains completely off all neurosuppressive and disease-modifying therapies (DMTs).
• Organic Recovery: Without the masking effects of Fampyra, her mobility and spasticity have demonstrated gradual, organic improvement on their own. She continues to safely manage her distinct cardiac and thyroid conditions.

Looking Forward

For a patient at EDSS 6.5 to successfully withdraw from neurosuppressive dependency while maintaining independent functional improvement is nothing short of a paradigm shift. It highlights the critical importance of evaluating structural cerebrovascular and neuroendocrine variables alongside neurodegenerative pathology.

We will continue longitudinal monitoring to measure the long-term sustainability of this biological intervention, but today, we celebrate a monumental step forward in progressive MS care.